Gilead wins U.S. nod for drug for all types of hepatitis C

Reuters Health Information: Gilead wins U.S. nod for drug for all types of hepatitis C

Gilead wins U.S. nod for drug for all types of hepatitis C

Last Updated: 2016-06-28

By Reuters Staff

(Reuters) - U.S. health regulators on Tuesday approved a combination drug by Gilead Sciences Inc that is the first available treatment for all six major forms of hepatitis C, advancing the company's leadership in the field and sending its shares up almost 4 percent.

Gilead has dominated the hepatitis C market over rivals AbbVie and Merck & Co with its high-priced and highly effective treatments Sovaldi (sofosbuvir) and the combination drug Harvoni (ledipasvir and sofosbuvir). The new treatment, to be sold under the brand name Epclusa, combines sofosbuvir, which was approved in 2013, with a new anti-viral drug velpatasvir.

Epclusa is approved for patients with and without cirrhosis. For those with moderate to severe cirrhosis, Epclusa must be taken with ribavirin, the Food and Drug Administration said.

"This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C," Edward Cox, director of the FDA's Office of Antimicrobial Products, said in a statement.

While the majority of U.S. patients have the genotype 1 form of hepatitis C, about 20 percent to 25 percent have genotypes 2 or 3, with small numbers infected with genotypes 4, 5 or 6. In other parts of the world, other genotypes are far more prevalent, such as in Egypt, where genotype 4 is widespread.

In pivotal clinical trials, Epclusa led to cure rates of 95 percent to 99 percent in patients without or with mild cirrhosis after 12 weeks of treatment. In a separate trial of patients with moderate to severe cirrhosis, cure rates of 94 percent were seen.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.